Case Report
Open Access Peer-reviewed

A Fatal Case of Prochlorperazine-Induced Neuroleptic Malignant Syndrome: A Case Report and Literature Review

Tariq Sharman
Department of Medicine, Heritage College of Osteopathic Medicine, Southern Ohio Medical Center, Ohio University, Portsmouth, Ohio, USA
American Journal of Medical Case Reports. 2019, 7(10), 253-259. DOI: 10.12691/ajmcr-7-10-8
Received June 14, 2019; Revised July 26, 2019; Accepted August 06, 2019

Abstract

Neuroleptic malignant syndrome (NMS) is a medical emergency associated with the use of neuroleptics and antiemetics. NMS is characterized by a distinctive clinical syndrome of altered mental status, rigidity, hyperthermia, and autonomic dysfunction. NMS occurs as a result of changes in presynaptic or postsynaptic dopamine signaling. Central D2 receptor blockade in the hypothalamus, nigrostriatal pathways, and spinal cord leads to increased muscular rigidity and tremor via extrapyramidal pathways. Hypothalamic D2 receptor blockade results in an elevated temperature set point and impairment of heat-dissipating mechanisms. The reported mortality rates for NMS vary between 5 to 20 percent and the occurrence of medical complications and disease severity are the strongest predictors of mortality. This is a case of a 51 year old Caucasian female who presented with altered mental status, temperature of 109°F, diffuse muscular rigidity and autonomic dysfunction manifested as labile blood pressure, tachypnea, hypoxemia and tachycardia after consuming 18 tablets of Prochlorperazine over three days for gastrointestinal upset. Her clinical presentation and laboratory work up were consistent with NMS and she developed fatal complications and multi-organ dysfunction secondary to Prochlorperazine-induced neuroleptic malignant syndrome.

Keywords:

neuroleptic malignant syndrome, serotonin syndrome, lethal catatonia, malignant hyperthermia, cholinergic crisis, rigidity, dysautonomia, dantrolene, bromocriptine, amantadine, creatine kinase, prochlorperazine, antipsychotic, antiemetic, seizure, dopamine, d2 receptor, dystonia, dyskinesia, benzodiazepines, electroconvulsive therapy, ect, hypothalamic, extrapyramidal
[1]  Delay J., Pichot P., Lemperiere T., Elissalde B., Peigne F. non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann. Med. Psychol. (Paris) 1960; 118(1): 145-152.
 
[2]  Gelenberg AJ; Bellinghausen B; Wojcik JD; Falk WE; Sachs GS. A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry. 1988; 145(4): 517-8.View Article  PubMed
 
[3]  Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989; 50(1): 18.
 
[4]  Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic Malignant Syndrome: Complications, Outcomes, and Mortality. Neurocrit Care. 2016; 24(1): 97.View Article  PubMed
 
[5]  Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993; 77(1): 185.View Article
 
[6]  Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?. Neurology. 1981; 31(2): 132.View Article  PubMed
 
[7]  Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000; 85(1): 129.View Article  PubMed
 
[8]  Gurrera RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia?. Clin Neuropharmacol. 2002; 25(4): 183.View Article  PubMed
 
[9]  Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome. Mov Disord. 1996; 11(6):726-8.View Article  PubMed
 
[10]  Keyser DL, Rodnitzky RL (1991). "Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy". Archives of Internal Medicine. 151(4): 794-6.View Article
 
[11]  Strawn JR, Keck PE, Caroff SN (2007). "Neuroleptic malignant syndrome". The American Journal of Psychiatry. 164 (6): 870-6.View Article  PubMed
 
[12]  Otani K; Horiuchi M; Kondo T; Kaneko S; Fukushima Y. Is the predisposition to neuroleptic malignant syndrome genetically transmitted?. Br J Psychiatry. 1991; 158:850-3.View Article  PubMed
 
[13]  Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Sano A, Koshiro K, Otani K, Kaneko S. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet. 2003; 117B(1): 57.View Article  PubMed
 
[14]  Pope HG Jr, Aizley HG, Keck PE Jr, McElroy SL. Neuroleptic malignant syndrome: long-term follow-up of 20 cases. J Clin Psychiatry. 1991; 52(5): 208.
 
[15]  Wu YF, Kan YS, Yang CH. Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson's disease--a case report. Gen Hosp Psychiatry. 2011 May; 33(3): 301. e7-8. Epub 2011 Jan 8.View Article  PubMed
 
[16]  Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan KA, Antelo RE, Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994; 182(3): 168.View Article  PubMed
 
[17]  Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989; 146(6): 717.View Article  PubMed
 
[18]  Hermesh H, Manor I, Shiloh R, Aizenberg D, Benjamini Y, Munitz H, Weizman A. High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. J Clin Psychopharmacol. 2002; 22(3): 252.View Article  PubMed
 
[19]  Lee JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry. 1998; 44(6): 499.View Article
 
[20]  Boyer EW, Shannon M. N Engl J Med. 2005; 352(11): 1112. The serotonin syndrome.View Article  PubMed
 
[21]  Birmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ. 2003; 168(11): 1439.
 
[22]  Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology. 1995;45(2):219.View Article  PubMed
 
[23]  Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000; 79(4): 201.View Article  PubMed
 
[24]  Fleischhacker WW, Unterweger B, Kane JM, Hinterhuber H. The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr Scand. 1990; 81(1): 3.View Article  PubMed
 
[25]  Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry. 1989; 146(3): 324.View Article  PubMed
 
[26]  Julia Park, Josh Tan, Sylvia Krzeminski, Maryam Hazeghazam, Meghana Bandlamuri and Richard W. Carlson, Malignant Catatonia Warrants Early Psychiatric-Critical Care Collaborative Management: Two Cases and Literature Review, Case Reports in Critical Care, 2017, (1), (2017).View Article  PubMed  PubMed
 
[27]  Caroff SN, Rosenberg H, Fletcher JE, Heiman-Patterson TD, Mann SC. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology. 1987;67(1):20.View Article  PubMed
 
[28]  Denborough M. Malignant hyperthermia. Lancet. 1998; 352(9134): 1131.View Article
 
[29]  MacLennan DH, Phillips MS. Malignant hyperthermia. Science. 1992; 256(5058): 789.View Article  PubMed
 
[30]  Wappler F. Malignant hyperthermia. Eur J Anaesthesiol. 2001; 18(10): 632.View Article  PubMed
 
[31]  Pileggi DJ, Cook AM. Neuroleptic Malignant Syndrome. Ann Pharmacother. 2016; 50(11): 973.View Article  PubMed
 
[32]  Addonizio G, Susman VL. ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome. J Clin Psychiatry. 1987 Mar; 48(3): 102-5.
 
[33]  Caroff SN, Mann SC, Keck PE Jr, Francis A. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol. 2000; 20(2): 257.View Article  PubMed
 
[34]  Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 1999; 33(5): 650.View Article  PubMed
 
[35]  Davis JM, Janicak PG, Sakkas P, Gilmore C, Wang Z. Electroconvulsive Therapy in the Treatment of the Neuroleptic Malignant Syndrome. Convuls Ther. 1991;7(2):111.
 
[36]  Morcos N, Rosinski A, Maixner DF. Electroconvulsive Therapy for Neuroleptic Malignant Syndrome: A Case Series. J ECT. 2019 Apr 22.View Article  PubMed
 
[37]  Harley JA, Peebles C, Porter RJ. Electroconvulsive therapy for catatonia secondary to neuroleptic malignant syndrome in a patient with multiple sclerosis. Aust N Z J Psychiatry. 2019 Jul; 53(7):703-704.View Article  PubMed
 
[38]  González-Romero MF, Avina-Galindo AM, Elbe D, Friedlander R, Vila-Rodriguez F. Lifesaving Electroconvulsive Therapy for a Child With Autism Spectrum Disorder, Severe Self-Injurious Behavior, and Neuroleptic Malignant Syndrome. J ECT. 2019 Apr 22.View Article  PubMed
 
[39]  Tural U, Onder E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci. 2010 Feb; 64(1): 79-87.View Article  PubMed
 
[40]  Nakamura M, Yasunaga H, Miyata H, Shimada T, Horiguchi H, Matsuda S. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry. 2012; 73(4): 427.View Article  PubMed